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The 2015 Nobel Prize in Physiology or Medicine has been 
awarded to Youyou Tu, William C. Campbell and Satoshi 
Ōmura for the discoveries of artemisinin and avermectin. 
Their efficacy on parasitic disease treatment won the recog-
nition of the whole world once again, revealing the dawning 
of the second “Golden age” in the development of natural 
products (http://dwz.cn/2u0RbE). Although artemisinin was 
originally innovated by Chinese, China holds neither pro-
prietary intellectual property, nor unique leading technology 
or international market shares. In the case of avermectin, the 
situation is totally the opposite. With the forthcoming of the 
fourth industrial revolution, lessons learned from the suc-
cess of avermectin may help transform China into a true 
powerhouse of innovation.  
The breakthrough and advances in technologies and in-
novations correlate well with the rising up of the superpow-
er nations in as seen throughout history. There have been 
three industrial revolutions since the mid-18th century. The 
first one is the age of water and steam power (17601840) 
that marks the transition from agricultural to industrial civi-
lization. The second one is the age of electric power 
(18401950), an age leading to the boom of steel, railways, 
chemical engineering and automobiles. With the new ener-
gy provided by oil and with worldwide communications 
speeding up, the economy was pushed towards globaliza-
tion. The third industrial revolution is the age of electronics 
and information technology, an age which began after 
World War II (1950). The fourth industrial revolution 
(2006) will fundamentally alter the way we live, work, and 
relate to each other. The ongoing synthetic biology guided 
by intelligent manufacturing covers the key achievements of 
digitization and networking. 
Synthetic biology has bridged engineering principles 
with biotechnology, thus making biological design much 
easier. This development will enable a paradigm shift in the 
fermentation industry from the sole pursuit of production 
scale to the increase of efficiency and productivity of se-
lected bacterial strains. Here, we review the history of the 
discovery of avermectin, the engineering of synthetic biol-
ogy and the industrialization of avermectin in China. These 
three realities combine and provide guidance for a new era 
of “innovation in China”. 
In 1974, Professor Ōmura at Kitasato Institute isolated a 
new species of Streptomyces from a soil sample collected at 
Kawana, Ito City, Shizuoka Prefecture, Japan. This strain 
was later identified as Streptomyces avermitilis by Merck 
Sharp and Dohme Research Laboratories; the Ōmura group 
succeeded in identifying the structure of avermectin in 1975 
from the fermentation broth of S. avermitilis. Dr. William 
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C. Campbell discovered ivermectin, a derivative of aver-
mectin, and highly effective against nematode parasites. 
From the 1980s, ivermectin has been widely applied in ag-
riculture, animal husbandry and pharmaceutical industry. 
Thanks to these discoveries, river blindness, the human dis-
ease caused by Onchocerca volvulus was eradicated. This is 
also true of the horse disease O. cervicalis (Figure 1). 
Moreover, avermectin was found to show a synergistic ef-
fect with methicillin (MET) against methicillin-resistant 
Staphylococcus aureus (MRSA) (Guo et al., 2014) by a 
high-throughput synergy screening strategy (Zhang et al., 
2007). These results shed light on potential therapeutics of 
anti-infective disease.  
Before the discovery of avermectin biosynthetic gene 
clusters, the methods of fermentation optimization and ran-
dom mutagenesis had been applied to improve avermectin 
production in the fermentation industry and the titer was 
increased from 0.009 g L1 to 0.5 g L1 (Siddique et al., 
2013). After the genome of S. avermitilis was sequenced 
(Ikeda et al., 2003), a more rational method called metabolic 
engineering was introduced and widely used. For example, 
the overexpression of malEFG, which encodes a maltose 
ATP-binding cassette transporter, increases the supply of 
precursors by improving the utilization rate of starch (Li et 
al., 2010). The overexpression of the ABC transporter 
AvtAB improves the efflux of avermectin (Qiu et al., 2011). 
The global regulator σHrdB was identified as a key factor 
targeting the only positive regulator gene aveR that is lo-
cated within the avermectin biosynthetic gene cluster. Mu-
tant A56 with high-avermectin production was obtained by 
high-throughput screening of a hrdB mutant library. This 
was further cultivated in a 180 m3 fermentor, and the pro-
duction of avermectin B1a reached 6.38 g L1 (Zhuo et al., 
2010). The regulatory elements exploited in Streptomyces 
by the method of synthetic biology facilitate the design and 
engineering of avermectin biosynthetic pathway (Bai et al., 
2015). In addition to this, other methods, such as the opti-
mization of fermentation medium, inoculation technique, 
isolation and extraction technology, cyclic utilization of 
 
 
Figure 1  Professor Ōmura at WHO headquarters with the statue showing 
a boy leading a blind adult caused by O. volvulus infection. Professor 
Ōmura appreciates the contribution of Chinese scientists and pharmaceuti-
cal companies on the research and industry development of avermectin.  
wastewater from fermentation, and carbohydrate supple-
ment process, not only increased the avermectin production, 
but at the same time also solved the problem of pollution 
from fermentation.  
In China, studies on avermectin began in 1984. Due to 
the great contributions of Professors Yinchu Shen and Jilun 
Li, large-scale industrial production was achieved. Professor 
Wen Liu did brilliant work on the optimization of compo-
nents of avermectin. Professor Ying Wen systematically 
studied the regulatory network for avermectin biosynthesis. 
A breakthrough on efflux pumps for avermectin was made 
by Professor Linquan Bai. Professors Wensheng Xiang and 
Zhongjun Qin made significant contributions on the re-
search and development of doramectin. Through collective 
efforts, researchers at the Institute of Microbiology Chinese 
Academy of Sciences (IMCAS) and their collaborators in-
creased the production of avermectin B1a with a titer to 9 g 
L1 and lowered the market price by forty times (Chen et al., 
2016). In April 2010, the avermectin industrial alliance 
(AIA) composed of thirteen avermectin manufacturers was 
established. In January 2013, the National Basic Research 
Program of China “Fitness study on the synthetic microbial 
systems” was funded by the Ministry of Science and Tech-
nology (MOST). This study targeted the improvement of 
avermectin production using synthetic biology approaches. 
China is the only avermectin producing country in the world 
now with an annual sale above three billion RMB. In the 
interpretation of the 2015 Nobel Prize in Physiology or 
Medicine by Professor Hualiang Jiang (http://dwz.cn/ 
2u0RbE), the contribution of IMCAS and AIA on avermec-
tin industry, as well as the work unraveling the novel 
mechanism of artemisinin endoperoxide formation reaction 
(Yan et al., 2015), were emphasized. S. avermitilis was also 
transformed into a valuable chassis and cell factory for oth-
er natural products (Bai et al., 2015). Moving beyond the 
“world factory”, China could become “a powerful fermen-
tation country” with the help of synthetic and system bio-
technology.  
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